References
- Biomarkers DefinitionsWorking Group. Biomarkers and Surrogate End Points: Preferred Definitions and Conceptual Framework. Clin. Pharmacol. Ther. 2001, 69(3), 89–95. DOI: 10.1067/mcp.2001.113989.
- The Huntington’s Disease Collaborative Research Group. A Novel Gene Containing A Trinucleotide Repeat that Is Expanded and Unstable on Huntington’s Disease Chromosomes. Cell. 1993, 72, 971–983. DOI: 10.1016/0092-8674(93)90585-e.
- Jimenez-Sanchez, M.; Licitra, F.; Underwood, B. R.; Rubinsztein, D. C. Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Cold Spring Harb. Perspect. Med. 2017, 7, a024240. DOI: 10.1101/cshperspect.a024240.
- Dickey, A. S.; Albert R, A. S.; La Spada, A. R.; Therapy Development in Huntington Disease: From Current Strategies to Emerging Opportunities. Am. J. Med. Genet. 2018, 176(4), 842–861. DOI: 10.1002/ajmg.a.38494.
- Silajdžić, E.; Björkqvist, M.; Critical, A. Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward. J. Huntington’s Dis. 2018, 7, 109–135. DOI: 10.3233/JHD-170273.
- Valentin, M.-A.; Shenglin, M.; Zhao, A.; Legay, F.; Avrameas, A. Validation of Immunoassay for Protein Biomarkers: Bioanalytical Study Plan Implementation to Support Pre-Clinical and Clinical Studies. J. Pharm. Biomed. Anal. 2011 15, 55(5), 869–877. DOI: 10.1016/j.jpba.2011.03.033.
- https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/